GHRP-6 vs Sermorelin Acetate

GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that functions as a potent ghrelin receptor (GHS-R1a) agonist, stimulating the anterior pituitary to release growth hormone in a pulsatile manner. Its mechanism involves both direct pituitary stimulation and hypothalamic amplification through GHRH neurons, producing robust GH elevations that mimic natural secretory patterns. Research published in the Journal of Endocrinology demonstrated that GHRP-6 use in animal models produced significant GH release within 15-30 minutes, with peak levels 5-10 times above baseline. Studies by Bowers et al. (1991) were among the first to characterize its GH-releasing potency. Notably, research in Neuroscience Letters has indicated neuroprotective properties in ischemic brain injury models, where GHRP-6 reduced infarct volume and improved neurological outcomes through anti-apoptotic pathways. Compared to other GH secretagogues like Ipamorelin and GHRP-2, GHRP-6 produces the strongest appetite-stimulating effect due to its ghrelin-mimetic activity. It also raises cortisol and prolactin to a greater degree than Ipamorelin, making it less selective but more potent in overall GH output. GHRP-2 shares similar potency but with slightly reduced hunger effects. For storage, lyophilized GHRP-6 should be kept at -20C for long-term preservation. Once reconstituted with bacteriostatic water, store at 2-8C and use within 4 weeks. This peptide is widely studied by endocrinologists, neuroscientists investigating ischemia-reperfusion injury, and researchers examining growth hormone physiology and appetite regulation pathways.

Sermorelin Acetate

Sermorelin acetate is a synthetic 29-amino acid peptide corresponding to the first 29 residues of the 44-amino acid human growth hormone-releasing hormone (GHRH 1-29). It represents the shortest fully functional fragment of GHRH capable of activating the GHRH receptor on anterior pituitary somatotrophs. Sermorelin was FDA-approved (marketed as Geref) for diagnostic evaluation of pituitary GH secretory capacity and was previously used in pediatric growth hormone deficiency research. Its mechanism involves GHRH-R binding, which activates adenylyl cyclase-cAMP-PKA signaling to stimulate GH gene transcription, synthesis, and pulsatile release. Clinical studies by Vittone et al. (Journal of Clinical Endocrinology and Metabolism, 1997) demonstrated that sermorelin use in elderly subjects increased GH secretion and improved body composition markers including lean body mass and skin thickness. Importantly, because sermorelin works through the native GHRH receptor, GH release remains subject to somatostatin-mediated negative feedback, preserving physiological regulation unlike direct GH use. Research has also explored sermorelin in cardiovascular contexts, where GH-IGF-1 axis activation may support cardiac tissue remodeling, and in seizure models where GHRH receptor activation appears to have neuroprotective effects. Compared to CJC-1295 (with or without DAC), sermorelin has a shorter half-life of approximately 10-20 minutes, requiring more frequent use but producing very precise, physiological GH pulses. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 14 days. Sermorelin is studied by pediatric endocrinology research centers, geriatric medicine departments, and cardiovascular research institutions investigating GH axis modulation.

Frequently Asked Questions